Inhibition of jejunal water and electrolyte absorption by therapeutic doses of clindamycin in man.
A steady-state perfusion technique has been used in vivo in normal subjects to show that at concentrations occurring during therapeutic use (500 mg/1, 1.1 mmol/l) the antibiotic clindamycin reversibly inhibits bicarbonate-stimulated water and electrolyte absorption from the human jejunum. Lactose-stimulated water and electrolyte absorption was not affected by the addition of clindamycin at the same concentration. Clindamycin-induced malabsorption of water and electrolytes may contribute significantly to the diarrhoea that occurs during clindamycin therapy in the absence of pseudomembranous colitis.
D000293:Adolescent; D000328:Adult; D001639:Bicarbonates / Q000378:metabolism; D001834:Body Water / Q000378:metabolism*; D002712:Chlorides / Q000378:metabolism; D002981:Clindamycin / Q000494:pharmacology*; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D007583:Jejunum / Q000378:metabolism*; D007785:Lactose / Q000378:metabolism; D008353:Mannitol / Q000378:metabolism; D012964:Sodium / Q000378:metabolism
D001639:Bicarbonates; D002712:Chlorides; D008353:Mannitol; D002981:Clindamycin; D012964:Sodium; D007785:Lactose